Canaccord’s Richard Davis anticipates VEEV stock can move up consistently sometime by the first half of next year.
Guggenheim’s Rohit Vanjani puts a price tag on Revance Therapeutics.
With the tremendous focus on the opioid crisis, Raymond James’ Elliot Wilbur sees exciting potential for Adamis.
Canaccord’s John Newman sees 24% upside potential for BLUE shares.
BTIG’s Tim Chiang still spots challenges in VRX’s orbit, but likewise pinpoints strength in eyecare business Bausch + Lomb, which boasts robust international gains.
Now that ADMP has submitted a PAS for its pediatric version of Symjepi, an epipnephrine injection cheaper than Mylan’s EpiPen, FBR’s Andrew D’silva sees a potential approval with less risk than the original version.
Maxim’s McCarthy now sees 27% upside potential for Gilead, impressed with management’s plans for lymphoma asset Yescarta.
Cantor’s William Tanner smirks as bears run low on “ammunition” to doubt TXMD on the heels of news of an NDA resubmission to the FDA for TX-004.
Mizuho’s Irina Rivkind Koffler may remain apprehensive on generics competition, but the analyst likes what she sees with new plans for corporate restructuring.
Teva has stirred up Street excitement with news of executive changes and an organizational overhaul.